Yes, but both drugs can lower blood pressure, so your doctor may monitor your readings and adjust doses to avoid symptomatic hypotension.
Report the symptoms promptly; topical or oral antifungal therapy is usually effective, and your prescriber may advise temporary discontinuation if infections recur.
Moderate alcohol consumption is permissible, but excessive intake can increase the risk of dehydration and ketoacidosis. Stay well-hydrated and discuss your drinking habits with your clinician.
Because of the osmotic diuresis, many patients experience modest weight loss (typically 2-3 kg) during the first few months of therapy.
Invokana can be prescribed for patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m²) to slow kidney disease progression, but it is contraindicated in severe renal failure.
Glycaemic reductions are usually seen within 2-4 weeks, with maximal effect achieved after about 12 weeks of consistent use.
All SGLT2 inhibitors share the same basic mechanism, but they differ slightly in potency, approved dosages, and specific cardiovascular or renal outcome data. Invokana is the only SGLT2 inhibitor approved in the UK at a 100 mg dose.
Your healthcare team may advise more frequent glucose monitoring during the first few weeks to assess response and detect any hypoglycaemia, especially if you are also taking insulin or sulfonylureas.
When used as monotherapy, Invokana carries a low risk of hypoglycaemia because its glucose-lowering effect depends on kidney filtration. The risk rises when combined with insulin or insulin-secretagogues.
Yes, keep the tablets in their original packaging with the prescription label, and declare them at security if required. Ensure you have enough supply for the entire trip, as obtaining a repeat prescription abroad may be difficult.
Invokana is a prescription-only medicine (POM) marketed in the United Kingdom by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The active ingredient in Invokana is canagliflozin, a member of the sodium-glucose co-transporter-2 (SGLT2) inhibitor class. It is supplied as a 100 mg oral pill and is approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of type 2 diabetes mellitus.
Canagliflozin blocks the SGLT2 protein located in the proximal tubules of the kidney. Under normal conditions, SGLT2 reabsorbs about 90 % of the filtered glucose back into the bloodstream. By inhibiting this transporter, Invokana reduces glucose reabsorption, leading to:
The drug begins to act within a few hours of ingestion, reaches peak plasma concentrations in 1-2 hours, and its glucose-lowering effect persists for 24 hours, allowing once-daily dosing.
Invokana is approved in the UK for the following indications:
These indications are supported by data from large, randomised clinical trials such as the CREDENCE and CANVAS Program studies, and they are reflected in the product’s Summary of Product Characteristics (SmPC) approved by the MHRA.
Type 1 Diabetes - Small observational studies have explored canagliflozin as an adjunct to insulin in type 1 diabetes to improve glycaemic control. This use is not approved by the MHRA, and the risk of diabetic ketoacidosis (DKA) is higher in this population. Off-label use requires strict medical supervision.
Heart Failure with Reduced Ejection Fraction (HFrEF) in Non-Diabetic Patients - International trials (e.g., DAPA-HF, EMPEROR-Reduced) have shown benefits of SGLT2 inhibitors in heart failure irrespective of diabetes status. While canagliflozin is not yet licensed for this specific indication in the UK, clinicians may consider it in specialist settings when other evidence-based options are unsuitable.
Off-label applications must be discussed with a qualified healthcare professional and are undertaken at the prescriber’s discretion.
Canagliflozin is primarily metabolised by UDP-glucuronosyltransferases (UGT1A9, UGT2B4) and has limited involvement with CYP enzymes, so clinically significant CYP-mediated interactions are uncommon.
This article provides educational information about Invokana and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
